Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2002 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ARESTIN

« Back to Dashboard
Arestin is a drug marketed by Orapharma and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

The generic ingredient in ARESTIN is minocycline hydrochloride. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for Tradename: ARESTIN

Suppliers: see list1

Pharmacology for Tradename: ARESTIN

Drug ClassTetracycline-class Drug

Clinical Trials for: ARESTIN

Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy
Status: Recruiting Condition: Lung Cancer

Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer
Status: Recruiting Condition: Head And Neck Cancer

Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome
Status: Active, not recruiting Condition: Angelman Syndrome

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer
Status: Active, not recruiting Condition: Esophageal Cancer

Minocycline Therapy for Management of Adverse Radiation Effects
Status: Not yet recruiting Condition: Irradiation; Adverse Effect

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil
Status: Active, not recruiting Condition: Lung Cancer

Minocycline and Aspirin in the Treatment of Bipolar Depression
Status: Recruiting Condition: Bipolar Disorder Depression

Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
Status: Recruiting Condition: Colorectal Cancer

Minocycline in Clinically Isolated Syndromes (CIS)
Status: Active, not recruiting Condition: Clinically Isolated Syndromes; Early Single Relapse of Multiple Sclerosis

A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients
Status: Recruiting Condition: Intracerebral Hemorrhage

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
minocycline hydrochloride
Powder, Extended Release; Dental050781-001FEB 16, 2001RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn